AstraZeneca's Ultomiris Disappoints In ALS, Setting Back Rare Disease Ambitions
Phase III CHAMPION-ALS Study Discontinued
Executive Summary
AstraZeneca is discontinuing a Phase III trial of the long-acting complement inhibitor it gained via its Alexion acquisition in amyotrophic lateral sclerosis because of lack of efficacy in an interim analysis. Interest is now turning to antisense and cell therapy candidates from other companies that are in late-stage development for the condition.
You may also be interested in...
Biohaven’s Non-Migraine Portfolio Takes Another Hit As Verdiperstat Fails In ALS
Pfizer is buying Biohaven's migraine portfolio, but the rest of the pipeline is poised to be spun out and there have been two development setbacks. Despite verdiperstat's failure in ALS, the field had a same-day win with Amylyx's Relyvrio approval.
Mitsubishi’s Oral Radicava Provides Convenience Option For ALS
Oral or feeding tube administration of the cerebral neuroprotectant should offer flexible dosing options for amyotrophic lateral sclerosis patients, the firm says.
AstraZeneca Goes All In On AL Amyloidosis With Caelum Acquisition
AstraZeneca’s recently-acquired Alexion unit is paying $150m upfront to buy the remainder of Caelum Biosciences and its late-stage therapy for light chain amyloidosis, a rare disease in which misfolded amyloid proteins build up in organs throughout the body, including the heart and kidneys.